Clinical Policy: Celiac Disease Laboratory Testing Reference Number: CP.MP.HN255
|
|
- Cleopatra O’Neal’
- 6 years ago
- Views:
Transcription
1 Clinical Policy: Reference Number: CP.MP.HN255 Effective Date: 02/06 Last Review Date: 7/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory and legal information. Description Celiac disease is a disorder of the small bowel disorder with mucosal inflammation, villous atrophy, and crypt hyperplasia, when gluten is ingested and improves with gluten is eliminated from the diet. Celiac disease can be categorized into degrees such as asymptomatic, silent with no evident malabsorption or other disease manifestations or potential, positive celiac-specific serology with normal histology. Serological testing is useful in the diagnosis and management of celiac disease. Asymptomatic patients without a family history of celiac disease or laboratory or clinical evidence for malabsorption can be considered to be low risk. The benefit of population screening for asymptomatic celiac disease has not yet been demonstrated. Policy/Criteria I. It is the policy of Health Net of California that the following serological tests for Celiac Disease are considered medically necessary for any of the following: A. Immunoglobulin A (IgA) anti-tissue transglutaminase (TTG), (also referred to as TTG-IgA) testing, or IgA anti-endomysial antibodies (IgA-EMA) testing for detection of celiac disease (CD) in individuals over the age of 2 years is considered medically necessary in any of the following: 1.Individuals with symptoms, signs, or laboratory evidence suggestive of malabsorption, (e.g., chronic diarrhea with weight loss, steatorrhea, postprandial abdominal pain, bloating) 2.Individuals with symptoms, signs, or laboratory evidence for which CD is a treatable cause 3.Individuals with a first-degree family member who has a confirmed diagnosis of CD when the individual shows possible signs or symptoms or laboratory evidence of CD. 4.Individuals with elevated serum aminotransferase levels when no other etiology is found 5.Individuals with Type I diabetes mellitus (DM) if there are any digestive symptoms, or signs, or laboratory evidence suggestive of CD. B. Measurement of total IgA, when there exists a high probability of CD and the ossibility of IgA deficiency. (IgA deficiency is more common in CD than in the general population). An alternative approach is to include both IgA and IgG-based testing, such as IgG-deamidated gliadin peptides (DGPs), in these high-probability individuals. C. IgG-based testing (IgG DGPs and IgG TTG) in individuals when a low IgA or selective IgA deficiency is identified Page 1 of 10
2 D. IgA TTG test in combination with DGP (IgA and IgG) in children younger than 2 years of age when CD is suspected E. HLA-DQ2 / DQ8 genotyping testing to rule out the disease in selected clinical situations. (HLA-DQ2 / DQ8 testing should not be used routinely in the initial diagnosis of CD). Examples of such clinical situations include but are not limited to: 1.Equivocal small-bowel histological finding (Marsh I-II) in seronegative individuals 2. Evaluation of individuals on a gluten free diet (GFD) in whom no testing for CD was done before GFD 3. Individuals with discrepant celiac-specific serology and histology 4. Individuals with suspicion of refractory CD where the original diagnosis of celiac remains in question 5. Individuals with Down's syndrome F. Serologic testing is also useful in monitoring the response to gluten-free diet. (Serum levels of IgA-EMA and IgA-TTG fall on a gluten-free diet and the test often becomes negative in treated patients) II. It is the policy of Health Net of California to consider screening for asymptomatic celiac disease, using the IgA endomysial or IgG ttg assays, investigational, as studies have noted lower sensitivity and specificity, and their benefit has not yet been demonstrated. Although potential advantages of screening for asymptomatic celiac disease exist, additional peerreviewed studies are needed to determine if this type of testing should be advocated. Background Celiac disease, also referred to as Celiac Sprue or gluten-sensitive enteropathy, is a chronic malabsorption disorder of the small intestine caused by exposure to dietary gluten in genetically predisposed individuals. Although celiac disease has been considered rare, studies suggest its prevalence is much greater than previous estimates, and may affect as many as 3 million Americans. The genetic predisposition to celiac disease is attributed to the specific genetic markers known as HLA-DQ2 and HLA-DQ8 that are present in affected individuals. Of the patients with celiac disease, 95% are human leukocyte antigen (HLA)-DQ2 or HLA-DQ8 positive. When these individuals are exposed to dietary proteins present in wheat, barley, and rye, known as glutens, they interact with these HLA molecules to activate an abnormal mucosal immune response and induce tissue damage Certain populations have an increased prevalence of celiac disease, including first and seconddegree relatives of individuals with biopsy-proven celiac disease. In addition, individuals with type 1 diabetes mellitus, Down syndrome, Turner syndrome, Williams syndrome, selective IgA deficiency, and autoimmune disorders have an increased prevalence. Celiac disease is characterized by chronic inflammation of the small intestinal mucosa that may result in atrophy of intestinal villi, a lowering of the villous height to crypt depth ratio, an Page 2 of 10
3 increase in intraepithelial lymphocytes, extensive surface cell damage and infiltration of the lamina propria with inflammatory cells leading to malabsorption, and exhibit a variety of clinical manifestations. Although previously thought to be a disease of childhood, it may occur at any age, with the classic presentation of diarrhea and malabsorption occurring less often, while atypical and silent presentations increasing. Presenting symptoms of adults include weight loss, diarrhea, lassitude, and anemia. Symptoms in children include failure to thrive, vomiting, diarrhea, muscle wasting, signs of hypoproteinemia and general irritability. It is not uncommon for celiac disease to present with extraintestinal manifestations, with little or no gastrointestinal symptoms, as in the case of dermatitis herpetiformis. Other presentations are unexplained short stature, delayed puberty, infertility, recurrent fetal loss, osteoporosis, vitamin deficiencies, fatigue, protein calorie malnutrition, recurrent aphthous stomatitis, elevated transaminases, and dental enamel hypoplasia. Untreated celiac disease may lead to vitamin and mineral deficiencies, an increased risk of gastrointestinal malignancies and intestinal lymphoma, osteoporosis, and other extraintestinal problems. Treatment of celiac disease is a lifelong gluten-free diet, omitting wheat, rye, and barley from the diet, which results in remission for most individuals. Even small quantities of gluten may be harmful. Oats may be permitted, however, their inclusion in a gluten-free diet is limited by potential contamination with gluten during processing. Compliance with the glutenfree diet is extremely challenging due to the poor palatability of gluten-free foods and confusing food-labels. The diagnosis of celiac disease is established by serological testing, biopsy evidence of villous atrophy, and improvement of symptoms on a gluten-free diet. According to a NIH Consensus Panel Statement on celiac disease (2004), testing should begin with serologic evaluation. Current serum immunologic markers for celiac disease have increased the sensitivity and specificity for diagnosing the disease. Because 2 to 3 percent of individuals with celiac sprue have selective IgA deficiency, IgA levels should also be measured. Serologic testing may not be as accurate in children less than age five. Based on very high sensitivities and specificities, the best available tests are the IgA antihuman tissue transglutaminase (TTG) and IgA endomysial antibody immunofluorescence (EMA) tests. Endomysial antibodies bind to connective tissue surrounding smooth muscle cells and are moderately sensitive and highly specific for untreated celiac disease. Even low titers of serum IgA endomysial antibodies are indicative of celiac disease. Serum levels of IgA endomysial antibody fall on a gluten-free diet and the test often becomes negative in treated patients. The IgA and IgG antigliadin antibody tests have lower diagnostic accuracy with frequent false positive results. Per the NIH Consensus Panel Statement, the IgA and IgG antigliadin antibody tests are no longer recommended for the initial diagnostic evaluation or screening, however, they may be useful for monitoring the response to a gluten-free diet. Page 3 of 10
4 According to the NIH Consensus Statement, when the diagnosis of celiac disease is uncertain because of indeterminate results, testing for certain genetic markers (HLA haplotypes) can stratify individuals to high or low risk for celiac disease. The consensus statement noted that greater than 97% of patients with celiac disease have the DQ2 and/or DQ8 marker, compared to about 40% of the general population. Therefore, an individual negative for DQ2 or DQ8 is extremely unlikely to have celiac disease (high negative predictive value). Serum IgA endomysial and tissue transglutaminase antibody testing have the highest diagnostic accuracy. The IgA and IgG antigliadin antibody tests have lower diagnostic accuracy with frequent false positive results as compared with IgA ttg and IgA DGP assays and are therefore no longer recommended for initial diagnostic evaluation or screening. The newer antideamidated gliadin peptide (DGP) assays show high diagnostic accuracy. IgA EMA, IgA ttg, IgA DGP and IgG DGP levels fall with treatment; as a result, these assays can be used as a noninvasive means of monitoring the response to a gluten-free diet. The recent guidelines from the American College of Gastroenterology on the diagnosis and management of Celiac Disease (2013) make the following recommendations regarding serologic testing: 1. Patients with symptoms, signs, or laboratory evidence suggestive of malabsorption, such as chronic diarrhea with weight loss, steatorrhea, postprandial abdominal pain, and bloating, should be tested for CD. (Strong recommendation, high level of evidence) 2. Patients with symptoms, signs, or laboratory evidence for which CD is a treatable cause should be considered for testing for CD. (Strong recommendation, moderate level of evidence) 3. Patients with a first-degree family member who has a confirmed diagnosis of CD should be tested if they show possible signs or symptoms or laboratory evidence of CD. (Strong recommendation, high level of evidence) 4. Consider testing of asymptomatic relatives with a first degree family member who has a confirmed diagnosis of CD. (Conditional recommendation, high level of evidence) 5. CD should be sought among the explanations for elevated serum aminotransferase levels when no other etiology is found. (Strong recommendation, high level of evidence) 6. Patients with Type I diabetes mellitus (DM) should be tested for CD if there are any digestive symptoms, or signs, or laboratory evidence suggestive of CD. (Strong recommendation, high level of evidence) 7. Immunoglobulin A (IgA) anti-tissue transglutaminase (TTG) antibody is the preferred single test for detection of CD in individuals over the age of 2 years. (Strong recommendation, high level of evidence) 8. When there exists a high probability of CD wherein the possibility of IgA deficiency is considered, total IgA should be measured. An alternative approach is to include both IgA and IgG-based testing, such as IgG-deamidated gliadin peptides (DGPs), in these highprobability patients. (Strong recommendation, moderate level of evidence) Page 4 of 10
5 9. In patients in whom low IgA or selective IgA deficiency is identified, IgG-based testing (IgG DGPs and IgG TTG) should be performed. (Strong recommendation, moderate level of evidence) 10. If the suspicion of CD is high, intestinal biopsy should be pursued even if serologies are negative. (Strong recommendation, moderate level of evidence) 11. All diagnostic serologic testing should be done with patients on a gluten-containing diet. (Strong recommendation, high level of evidence) 12. Antibodies directed against native gliadin are not recommended for the primary detection of CD. (Strong recommendation, high level of evidence) 13. Combining several tests for CD in lieu of TTG IgA alone may marginally increase the sensitivity for CD but reduces specificity and therefore are not recommended in low-risk populations. (Conditional recommendation, moderate level of evidence) 14. When screening children younger than 2 years of age for CD, the IgA TTG test should be combined with DGP (IgA and IgG). (Strong recommendation, moderate level of evidence) 15. The confirmation of a diagnosis of CD should be based on a combination of findings from the medical history, physical examination, serology, and upper endoscopy with histological analysis of multiple biopsies of the duodenum. (Strong recommendation, high level of evidence) 16. HLA-DQ2 / DQ8 testing should not be used routinely in the initial diagnosis of CD. (Strong recommendation, moderate level of evidence) 17. While standard diagnostic tests (specific serology and intestinal biopsy) have a high PPV for CD, they should not be relied upon to exclude CD in patients already adhering to a GFD. (Strong recommendation, high level of evidence) 18. HLA-DQ2 / DQ8 genotyping should be used to try to exclude CD prior to embarking on a formal gluten challenge. (Strong recommendation, high level of evidence) 19. Monitoring of adherence to GFD should be based on a combination of history and serology (IgA TTG or IgA (or IgG) DGP antibodies). (Strong recommendation, moderate level of evidence) Coding Implications This clinical policy references Current Procedural Terminology (CPT ). CPT is a registered trademark of the American Medical Association. All CPT codes and descriptions are copyrighted 2015, American Medical Association. All rights reserved. CPT codes and CPT descriptions are from the current manuals and those included herein are not intended to be all-inclusive and are included for informational purposes only. Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services. Not an all inclusive list CPT Codes Description Page 5 of 10
6 CPT Codes Description HLA Class II typing, high resolution (ie, alleles or allele groups); one locus (eg, HLA-DRB1, -DRB3/4/5, -DQB1, -DQA1, -DPB1, or -DPA1), each Gammaglobulin; IgA, IgD, IgG, IgM, each Immunoassay for analyte other than infectious agent antibody or infectious agent antigen, qualitative or semiquantitative; multiple step method [covered for IgG and IgA deamidated gliadin antibodies (DGP)] [not covered for IgA Immunoassay, analyte, quantitative; not otherwise specified Fluorescent noninfectious agent antibody; screen, each antibody [covered for genetic testing for HLA-DQ2 and HLA-DQ8 haplotypes] [not covered for serological testing of antireticulin antibodies (ARA)] Antibody to human leukocyte antigens (HLA), solid phase assays (eg, microspheres or beads, ELISA, flow cytometry); qualitative assessment of the presence or absence of antibody(ies) to HLA Class I and/or Class II HLA antigens HCPCS Codes Description ICD-10-CM Diagnosis Codes that Support Coverage Criteria ICD-10-CM Description Code K90.0 Celiac disease Initial Approval 02/06 Update. Revision Diagnostic tests should be performed before the 3/08 initiation of gluten restriction begins, added to the policy statement. To monitor response to a gluten-free diet was removed from policy statement. (American Gastroenterological Association) Annual review no changes 2/11 9/12 Revised policy statement, removing testing of anti-gliadin antibodies, and 9/13 anti-reticulin antibodies as these tests are no longer recommended. Added 2013 recommendations from ACG guidelines on Celiac Disease. Code updates. Annual review no changes 4/14 4/15 4/16 Page 6 of 10
7 Update to new format 7/17 References 1. Armstrong D, Don-Wauchope AC, Verdu EF. Testing for gluten-related disorders in clinical practice: The role of serology in managing the spectrum of gluten sensitivity. Can J Gastroenterol. 2011; 25(4): Barakauskas VE, Lam GY, Estey MP. Digesting all the options: laboratory testing for celiac disease. Crit Rev Clin Lab Sci Dec;51(6): Bufler P, Heilig G, Ossiander G, et al. Diagnostic performance of three serologic tests in childhood celiac disease. Z Gastroenterol Feb;53(2): Bürgin-Wolff A, Mauro B, Faruk H. Intestinal biopsy is not always required to diagnose celiac disease: a retrospective analysis of combined antibody tests. BMC Gastroenterol Jan 23;13: Ciclitira PJ. Management of celiac disease in adults. UpToDate. May 14, Delgado JF, Amengual MJ, Veraguas A, et al. Pediatric celiac patients carrying the HLA-DR7-DQ2 and HLA-DR3-DQ2 haplotypes display small clinical differences. Acta Paediatr Jun;103(6):e Garnier-Lengliné H, Brousse N, Candon S, et al. Have serological tests changed the face of childhood coeliac disease? A retrospective cohort study. BMJ Open Nov 22;2(6). 8. Hayes. Celiac Disease. GTE Report. January 4, 2010, Updated January 11, Update Jan Updated January 14, Archived Feb Hayes. Medical Technology Directory. Serologic Assays for the Diagnosis and Management of Inflammatory Bowel Disease. July 28, 2003, Updated August 28, Hojsak I, Mozer-Glassberg Y, Segal GN, et al. Celiac Disease Screening Assays for Children Younger than 3 Years of Age: The Performance of Three Serological Tests. Dig Dis Sci Aug 17. [Epub ahead of print]. 11. Hope BC, Ameratunga R, Austin PM, et al. Diagnostic utility of modified gliadin Peptide antibody assays in new zealand children. J Pediatr Gastroenterol Nutr Jul;57(1): Hostoffer RW. Selective IgA deficiency: Clinical manifestations, pathophysiology, and diagnosis. UpToDate. August 3, Husby S, Murray JA. Diagnosing celiac disease and the potential for serological markers. Nat Rev Gastroenterol Hepatol Nov;11(11): Katz KD, Rashtak S, Lahr BD, et al. Screening for celiac disease in a north american population: sequential serology and gastrointestinal symptoms. Am J Gastroenterol Jul;106(7): Epub 2011 Mar Kelly CP. Diagnosis of celiac disease. UpToDate Updated June 18, Lewis NR, Scott BB. Meta-analysis: Deamidated gliadin peptide antibody and tissue transglutaminase antibody compared as screening tests for coeliac disease. Aliment Pharmacol Ther. 2010;31(1): Page 7 of 10
8 17. Ludvigsson JF, Zingone F, Tomson T, et al. Increased risk of epilepsy in biopsy-verified celiac disease: a population-based cohort study. Neurology 2012; 78: Makovicky P, Rimarova K, Boor A, et al. Correlation between antibodies and histology in celiac disease: Incidence of celiac disease is higher than expected in the pediatric population. Mol Med Rep Aug Mooney PD, Wong SH, Johnston AJ, et al. Increased Detection of Celiac Disease With Measurement of Deamidated Gliadin Peptide Antibody Before Endoscopy. Clin Gastroenterol Hepatol. 2015;13(7): Mubarak A, Spierings E, Wolters VM, et al. Children with celiac disease and high ttga are genetically and phenotypically different. World J Gastroenterol Nov 7;19(41): Neves MM, Gonzalez-Garcia MB, Nouws HP, et al. An electrochemical deamidated gliadin antibody immunosensor for celiac disease clinical diagnosis. Analyst. 2013;138(7): NIH Consensus Development Conference on Celiac Disease. National Institutes of Health Consensus Development Conference Statement. June 28 30, 2004 Available at: Pallav K, Kabbani T, Tariq S, et al. Clinical utility of celiac disease-associated HLA testing. Dig Dis Sci Sep;59(9): Plantier S, Harlé JR, Gautier M, et al. Immunological screening and follow-up of celiac disease: Experience of the University Hospital of Marseille. Rev Med Interne Aug Rozenberg O, Lerner A, Pacht A, et al. A new algorithm for the diagnosis of celiac disease. Cell Mol Immunol Mar;8 (2): Epub 2011 Feb Rubio-Tapia A, Hill ID, Kelly CP, et al. ACG clinical guidelines: diagnosis and management of celiac disease. Am J Gastroenterol May;108(5): Available at: Sandström O, Rosén A, Lagerqvist C, et al. Transglutaminase Iga Antibodies in A Celiac Disease Mass Screening and the Role of Hla-Dq Genotyping and Endomysial Antibodies in Sequential Testing. J Pediatr Gastroenterol Nutr Jun Schuppan D, Dietrich W. Pathogenesis, epidemiology, and clinical manifestations of celiac disease in adults. UpToDate. June 13, Schyum AC, Rumessen JJ. Serological testing for celiac disease in adults. 30. Shahnaz A, Maguire G, Parker R, et al. Tissue transglutaminase antibody levels predict IgA deficiency. Arch Dis Child Aug Srinivas M, Basumani P, Podmore G, et al. Utility of testing patients, on presentation, for serologic features of celiac disease. Clin Gastroenterol Hepatol Jun;12(6): United European Gastroenterol J Oct;1(5): van der Windt DA, Jellema P, Mulder CJ, et al. Diagnostic testing for celiac disease among patients with abdominal symptoms: A systematic review. JAMA. 2010;303(17): Page 8 of 10
9 34. Vaquero L, Caminero A, Nuñez A, et al. Coeliac disease screening in first-degree relatives on the basis of biopsy and genetic risk. Eur J Gastroenterol Hepatol Dec Vermeersch P, Geboes K, Mariën G, et al. Serological diagnosis of celiac disease: comparative analysis of different strategies. Clin Chim Acta Nov 12;413(21-22): Vermeersch P, Geboes K, Mariën G, et al. Diagnostic performance of IgG antideamidated gliadin peptide antibody assays is comparable to IgA anti-ttg in celiac disease. Clin Chim Acta Jul 4;411(13-14): Epub 2010 Feb Villalta D, Tonutti E, Prause C, et al. IgG antibodies against deamidated gliadin peptides for diagnosis of celiac disease in patients with IgA deficiency. Clin Chem. 2010;56(3): Wakim-Fleming J, Pagadala MR, Lemyre MS, et al. Diagnosis of celiac disease in adults based on serology test results, without small-bowel biopsy. Clin Gastroenterol Hepatol May;11(5): World Gastroenterology Organisation Global Guidelines. Celiac disease. April Available at: ong_final.pdf Important Reminder This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. Health Plan means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan s affiliates, as applicable. The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures. This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to Page 9 of 10
10 applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time. This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions. Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan. This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services. Note: For Medicaid members, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy. Note: For Medicare members, to ensure consistency with the Medicare National Coverage Determinations (NCD) and Local Coverage Determinations (LCD), all applicable NCDs, LCDs, and Medicare Coverage Articles should be reviewed prior to applying the criteria set forth in this clinical policy. Refer to the CMS website at for additional information Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene and Centene Corporation are registered trademarks exclusively owned by Centene Corporation. Page 10 of 10
See Policy CPT CODE section below for any prior authorization requirements
Effective Date: 1/1/2019 Section: LAB Policy No: 404 Medical Policy Committee Approved Date: 12/17; 12/18 1/1/19 Medical Officer Date APPLIES TO: All lines of business See Policy CPT CODE section below
More informationPrimary Care Update January 26 & 27, 2017 Celiac Disease: Concepts & Conundrums
Primary Care Update January 26 & 27, 2017 Celiac Disease: Concepts & Conundrums Alia Hasham, MD Assistant Professor Division of Gastroenterology, Hepatology & Nutrition What is the Preferred Initial Test
More informationNovember Laboratory Testing for Celiac Disease. Inflammation in Celiac Disease
November 2011 Gary Copland, MD Chair, Department of Pathology, Unity Hospital Laboratory Medical Director, AMC Crossroads Chaska and AMC Crossroads Dean Lakes Laboratory Testing for Celiac Disease Celiac
More informationDiagnostic Testing Algorithms for Celiac Disease
Diagnostic Testing Algorithms for Celiac Disease HOT TOPIC / 2018 Presenter: Melissa R. Snyder, Ph.D. Co-Director, Antibody Immunology Laboratory Department of Laboratory Medicine and Pathology, Mayo Clinic
More informationDiagnosis Diagnostic principles Confirm diagnosis before treating
Diagnosis 1 1 Diagnosis Diagnostic principles Confirm diagnosis before treating Diagnosis of Celiac Disease mandates a strict gluten-free diet for life following the diet is not easy QOL implications Failure
More informationBIOPSY AVOIDANCE IN CHILDREN: THE EVIDENCE
BIOPSY AVOIDANCE IN CHILDREN: THE EVIDENCE Steffen Husby Hans Christian Andersen Children s Hospital Odense University Hospital DK-5000 Odense C, Denmark Agenda Background Algorithm Symptoms HLA Antibodies
More informationEvidence Based Guideline
Evidence Based Guideline Serologic Diagnosis of Celiac Disease File Name: Origination: Last CAP Review: Next CAP Review: Last Review: serologic_diagnosis_of_celiac_disease 4/2012 Description of Procedure
More informationName of Policy: Human Leukocyte Antigen (HLA) Testing for Celiac Disease
Name of Policy: Human Leukocyte Antigen (HLA) Testing for Celiac Disease Policy #: 545 Latest Review Date: June 2015 Category: Laboratory Policy Grade: B Background/Definitions: As a general rule, benefits
More informationCELIAC DISEASE - GENERAL AND LABORATORY ASPECTS Prof. Xavier Bossuyt, Ph.D. Laboratory Medicine, Immunology, University Hospital Leuven, Belgium
CELIAC DISEASE - GENERAL AND LABORATORY ASPECTS Prof. Xavier Bossuyt, Ph.D. Laboratory Medicine, Immunology, University Hospital Leuven, Belgium 5.1 Introduction Celiac disease is a chronic immune-mediated
More informationDiseases of the gastrointestinal system Dr H Awad Lecture 5: diseases of the small intestine
Diseases of the gastrointestinal system 2018 Dr H Awad Lecture 5: diseases of the small intestine Small intestinal villi Small intestinal villi -Villi are tall, finger like mucosal projections, found
More informationMeredythe A. McNally, M.D. Gastroenterology Associates of Cleveland Beachwood, OH
Meredythe A. McNally, M.D. Gastroenterology Associates of Cleveland Beachwood, OH Case in point 42 year old woman with bloating, gas, intermittent diarrhea alternating with constipation, told she has IBS
More informationGluten Sensitivity Fact from Myth. Disclosures OBJECTIVES 18/09/2013. Justine Turner MD PhD University of Alberta. None Relevant
Gluten Sensitivity Fact from Myth Justine Turner MD PhD University of Alberta Disclosures None Relevant OBJECTIVES Understand the spectrum of gluten disorders Develop a diagnostic algorithm for gluten
More informationCeliac Disease 1/13/2016. Objectives. Question 1. Understand the plethora of conditions or symptoms that require testing for Celiac Disease (CD)
Celiac Disease MONTE E. TROUTMAN, DO, FACOI JANUARY 6, 2016 Objectives Understand the plethora of conditions or symptoms that require testing for Celiac Disease (CD) Develop a knowledge of testing needed
More informationName of Policy: Serologic Diagnosis of Celiac Disease
Name of Policy: Serologic Diagnosis of Celiac Disease Policy #: 161 Latest Review Date: September 2013 Category: Laboratory Policy Grade: A Background/Definitions: As a general rule, benefits are payable
More informationOHTAC Recommendation
OHTAC Recommendation Clinical Utility of Serologic Testing for Celiac Disease in Ontario Presented to the Ontario Health Technology Advisory Committee in April and October, 2010 December 2010 Background
More informationClinical Policy Title: Celiac disease diagnostic testing
Clinical Policy Title: Celiac disease diagnostic testing Clinical Policy Number: CCP.1049 Effective Date: December 1, 2013 Initial Review Date: August 21, 2013 Most Recent Review Date: August 7, 2018 Next
More informationThe first and only fully-automated, random access, multiplex solution for Celiac IgA and Celiac IgG autoantibody testing.
Bio-Rad Laboratories BIOPLEX 2200 SYSTEM BioPlex 2200 Celiac IgA and IgG Kits The first and only fully-automated, random access, multiplex solution for Celiac IgA and Celiac IgG autoantibody testing. The
More informationAm I a Silly Yak? Laura Zakowski, MD. No financial disclosures
Am I a Silly Yak? Laura Zakowski, MD No financial disclosures Patient NP 21 year old male with chronic headaches for 6 years extensively evaluated and treated Acupuncturist suggests testing for celiac
More informationOriginal Policy Date
MP 2.04.21 Serologic Diagnosis of Celiac Disease Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed with literature search/12:2013 Return to Medical
More informationIs It Celiac Disease or Gluten Sensitivity?
Is It Celiac Disease or Gluten Sensitivity? Mark T. DeMeo MD, FACG Rush University Med Center Case Study 35 y/o female Complains of diarrhea, bloating, arthralgias, and foggy mentation Cousin with celiac
More informationThe first and only fully-automated, random access, multiplex solution for Celiac IgA and Celiac IgG autoantibody testing.
Bio-Rad Laboratories bioplex 2200 SYSTEM BioPlex 2200 Celiac IgA and IgG Kits * The first and only fully-automated, random access, multiplex solution for Celiac IgA and Celiac IgG autoantibody testing.
More informationDEAMIDATED GLIADIN PEPTIDES IN COELIAC DISEASE DIAGNOSTICS
DEAMIDATED GLIADIN PEPTIDES IN COELIAC DISEASE DIAGNOSTICS Z. Vanickova 1, P. Kocna 1, K. Topinkova 1, M. Dvorak 2 1 Institute of Clinical Biochemistry & Laboratory Diagnostics; 2 4th Medical Department,
More informationChallenges in Celiac Disease. Adam Stein, MD Director of Nutrition Support Northwestern University Feinberg School of Medicine
Challenges in Celiac Disease Adam Stein, MD Director of Nutrition Support Northwestern University Feinberg School of Medicine Disclosures None Overview Celiac disease Cases Celiac disease Inappropriate
More informationCeliac Disease. Sheryl Pfeil, MD The Ohio State University Division of Gastroenterology, Hepatology, and Nutrition. January 2015
Celiac Disease Sheryl Pfeil, MD The Ohio State University Division of Gastroenterology, Hepatology, and Nutrition January 2015 Objectives Review the clinical presentation of celiac disease, including intestinal
More informationGluten-Free China Gastro Q&A
Gluten-Free China Gastro Q&A Akiko Natalie Tomonari MD akiko.tomonari@parkway.cn Gastroenterology Specialist ParkwayHealth Introduction (of myself) Born in Japan, Raised in Maryland, USA Graduated from
More informationEAT ACCORDING TO YOUR GENES. NGx-Gluten TM. Personalized Nutrition Report
EAT ACCORDING TO YOUR GENES NGx-Gluten TM Personalized Nutrition Report Introduction Hello Caroline: Nutrigenomix is pleased to provide you with your NGx-Gluten TM Personalized Nutrition Report based on
More informationSheila E. Crowe, MD, FACG
1A: Upper Gut Celiac Disease: When to Look and How? Sheila E. Crowe, MD, FACG Learning Objectives At the end of this presentation, the successful learner should be able to: Identify the many groups of
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Serologic Diagnosis of Celiac Disease Page 1 of 14 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Serologic Diagnosis of Celiac Disease Professional Institutional
More informationCoeliac disease. Do I have coeliac. disease? Diagnosis, monitoring & susceptibilty. Laboratory flowsheet included
Laboratory flowsheet included I have coeliac disease. What monitoring tests should be performed? Do I have coeliac disease? Are either of our children susceptible to coeliac disease? Monitoring tests Diagnostic
More informationPeter HR Green MD. Columbia University New York, NY
CELIAC DISEASE, 2008 Peter HR Green MD Celiac Disease Center Columbia University New York, NY pg11@columbia.edu DIAGNOSIS OF CELIAC DISEASE Presence of consistent pathology and response to a gluten-free
More informationDisclosures GLUTEN RELATED DISORDERS CELIAC DISEASE UPDATE OR GLUTEN RELATED DISORDERS 6/9/2015
Disclosures CELIAC DISEASE UPDATE OR GLUTEN RELATED DISORDERS 2015 Scientific Advisory Board: Alvine Pharmaceuticals, Alba Therapeutics, ImmunsanT Peter HR Green MD Columbia University New York, NY GLUTEN
More informationUnderstanding Celiac Disease
Understanding Diagnostic Challenges Sheryl Pfeil, MD Professor of Clinical Medicine Division of Gastroenterology, Hepatology and Nutrition Department of Internal Medicine The Ohio State University Wexner
More informationUnderstanding Celiac Disease
Understanding Celiac Disease Diagnostic Challenges Sheryl Pfeil, MD Professor of Clinical Medicine Division of Gastroenterology, Hepatology and Nutrition Department of Internal Medicine The Ohio State
More informationCONTEMPORARY CONCEPT ON BASIC APSECTS OF GLUTEN-SENSITIVE ENTEROPATHY IN ELDERLY PATIENTS
VIII, 2014, 1 33. 1,. 2,. - 1,. 1. 3 1,., 2,., 3, CONTEMPORARY CONCEPT ON BASIC APSECTS OF GLUTEN-SENSITIVE ENTEROPATHY IN ELDERLY PATIENTS Ts. Velikova 1, Z. Spassova 2,. Ivanova-Todorova 1, D. Kyurkchiev
More informationFollow-up Management of Patients with Celiac Disease: Resource for Health Professionals
Follow-up Management of Patients with Celiac Disease: Resource for Health Professionals Jocelyn Silvester, MD PhD FRCPC April 27, 2017 Research grants Disclosures Canadian Institutes of Health Research
More informationEpidemiology. The old Celiac Disease Epidemiology:
Epidemiology 1 1 Epidemiology The old Celiac Disease Epidemiology: A rare disorder typical of infancy Wide incidence fluctuates in space (1/400 Ireland to 1/10000 Denmark) and in time A disease of essentially
More informationNo relevant financial relationships to disclose
CELIAC DISEASE Michael H. Piper, MD, FACP, FACG Gastroenterology Program Director Chief of Gastroenterology Providence-Providence Park Hospitals/St. John Macomb Hospital No relevant financial relationships
More informationCeliac & Gluten Sensitivity; serum
TEST NAME: Celiac & Gluten Sensitivity (Serum) Celiac & Gluten Sensitivity; serum ANTIBODIES REFERENCE RESULT/UNIT INTERVAL NEG WEAK POS POSITIVE Tissue Transglutaminase (ttg) IgA 1420 U < 20.0 Tissue
More informationBaboons Affected by Hereditary Chronic Diarrhea as a Possible Non-Human Primate Model of Celiac Disease
Baboons Affected by Hereditary Chronic Diarrhea as a Possible Non-Human Primate Model of Celiac Disease Debby Kryszak 1, Henry McGill 2, Michelle Leland 2,, Alessio Fasano 1 1. Center for Celiac Research,
More informationAlliance for Best Practice in Health Education
Alliance for Best Practice in Health Education Objectives Following this program, participants will 1. List the clinical situations where celiac disease should be suspected 2. Distinguish between celiac
More informationNew Insights on Gluten Sensitivity
New Insights on Gluten Sensitivity Sheila E. Crowe, MD, FRCPC, FACP, FACG, AGAF Department of Medicine University of California, San Diego Page 1 1 low fat diet low carb diet gluten free diet low fat diet
More informationDiet Isn t Working, We Need to Do Something Else
Diet Isn t Working, We Need to Do Something Else Ciarán P Kelly, MD Celiac Center Beth Israel Deaconess Medical Center & Celiac Program Harvard Medical School Boston Gluten Free Diet (GFD) Very good but
More informationCeliac Disease. Gluten-Sensitive Enteropathy Celiac Sprue Non-tropical Sprue
Celiac Disease Gluten-Sensitive Enteropathy Celiac Sprue Non-tropical Sprue Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted
More informationCELIAC DISEASE. Molly Jennings Deb McCafferty MS, RD
CELIAC DISEASE Molly Jennings Deb McCafferty MS, RD WHAT IS CELIAC DISEASE? In short In this disease, exposure to gluten results in damge to the intestinal mucosa. Immune-mediated disorder Also known as
More informationCeliac Disease Ce. Celiac Disease. Barry Z. Hirsch, M.D. Baystate Pediatric Gastroenterology and Nutrition. baystatehealth.org/bch
Celiac Disease Ce Celiac Disease Barry Z. Hirsch, M.D. Baystate Pediatric Gastroenterology and Nutrition baystatehealth.org/bch Autoimmune Disease Inappropriate inflammation 1 1/21/15 Celiac Disease Classic
More informationSpectrum of Gluten Disorders
Food Intolerance:Celiac Disease and Gluten Sensitivity-A Guide for Healthy Lifestyles Ellen Karlin 2018 Spectrum of Gluten Disorders Wheat allergy - prevalence 3-8 % (up to 3 years old) Non-celiac gluten
More informationEsperanza Garcia-Alvarez MD Medical Director Pediatric Celiac Center at Advocate Children s Hospital
Esperanza Garcia-Alvarez MD Medical Director Pediatric Celiac Center at Advocate Children s Hospital Nothing to disclose Objectives Better understanding pathogenesis celiac disease Better understanding
More informationPresentation and Evaluation of Celiac Disease
Presentation and Evaluation of Celiac Disease C. CUFFARI, MD, FRCPC, FACG, AGAF The Johns Hopkins Hospital Baltimore MD. Main Points Celiac disease is not rare (1 in 100-300) It can present in many ways:
More informationCeliac Disease: The Past and The Present
Celiac Disease: The Past and The Present The Center for Celiac Research and Mucosal Biology Research Center University of Maryland School of Medicine Baltimore, Maryland, U.S.A. 1 Celiac Disease Roadmap:
More information*Please see amendment for Pennsylvania Medicaid at the end
1 of 28 Number: 0561 Policy *Please see amendment for Pennsylvania Medicaid at the end of this CPB. I. Aetna considers serological testing of IgA anti human tissue transglutaminase (TTG) antibodies, IgG
More informationClinical Policy Title: Diagnostic testing for celiac disease
Clinical Policy Title: Diagnostic testing for celiac disease Clinical Policy Number: 02.07.01 Effective Date: December 1, 2013 Initial Review Date: August 21, 2013 Most Recent Review Date: August 17, 2016
More informationBy Mathew P. Estey, PhD, FCACB; and Vilte E. Barakauskas, PhD, DABCC, FCACB
1 of 5 2015-07-10 11:15 AM Evolution of Celiac Disease Testing The laboratory is challenged to provide guidance on test ordering and interpretation while ensuring accurate performance and appropriate test
More informationCeliac Disease. Detlef Schuppan HARVARD MEDICAL SCHOOL
Celiac Disease Detlef Schuppan Falk Symposium in the Intestinal Tract: Pathogenesis and Treatment, Kiev,, Ukraine, May 15-16, 16, 2009 HARVARD MEDICAL SCHOOL Celiac Disease Intolerance to gluten from wheat,
More informationCELIAC SPRUE. What Happens With Celiac Disease
CELIAC SPRUE Celiac Disease (CD) is a lifelong, digestive disorder affecting children and adults. When people with CD eat foods that contain gluten, it creates an immune-mediated toxic reaction that causes
More informationUpdate on Celiac Disease: New Standards and New Tests
IMPROVING PATIENT CARE THROUGH ESOTERIC LABORATORY TESTING JUNE 2008 Update on Celiac Disease: New Standards and New Tests The National Institutes of Health (NIH) has reported that as many as 1% (3,000,000)
More informationCeliac Disease. Samuel Gee (1888) first described Celiac disease in On the Coeliac Affection Gluten sensitive entropathy Non-tropical sprue
Celiac disease Mohammad Rostami Nejad, PhD Head of Celiac disease department Gastroenterology and Liver Diseases Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran Celiac Disease
More informationLiving with Coeliac Disease Information & Support is key
Living with Coeliac Disease Information & Support is key Mary Twohig Chairperson Coeliac Society of Ireland What is Coeliac Disease? LIVING WITH COELIAC DISEASE Fact Not Fad Auto immune disease - the body
More informationCeliac disease is a unique disorder that is both a food
GASTROENTEROLOGY 2006;131:1981 2002 American Gastroenterological Association () Institute Technical Review on the Diagnosis and Management of Celiac Disease This technical review addresses the state of
More informationGluten Free and Still Symptomatic
How many celiac patients are affected? Gluten Free and Still Symptomatic 6.2% of all celiac patients have continuing diarrhea after 2 years on a gluten free diet 18% will develop constipation in this time
More informationClinical updates on diagnosing glutensensitive enteropathy
Editorial Acta Medica Academica 2011;40(2):105-109 DOI 10.5644/ama2006-124.13 Clinical updates on diagnosing glutensensitive enteropathy Faruk Hadziselimovic 1, 2, Annemarie Bürgin-Wolff 1 1 Institute
More informationScreening for Celiac Disease: A Systematic Review for the U.S. Preventive Services Task Force
Evidence Synthesis Number 144 Screening for Celiac Disease: A Systematic Review for the U.S. Preventive Services Task Force Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health
More informationSlides and Resources.
Update on Celiac Disease Douglas L. Seidner, MD, AGAF, FACG Director, Center for Human Nutrition Vanderbilt University As revised/retold by Edward Saltzman, MD Tufts University None Disclosures This ppt
More informationHealth Canada s Position on Gluten-Free Claims
June 2012 Bureau of Chemical Safety, Food Directorate, Health Products and Food Branch 0 Table of Contents Background... 2 Regulatory Requirements for Gluten-Free Foods... 2 Recent advances in the knowledge
More informationDDW WRAP-UP 2012 CELIAC DISEASE. Anju Sidhu MD University of Louisville Gastroenterology, Hepatology and Nutrition June 21, 2012
DDW WRAP-UP 2012 CELIAC DISEASE Anju Sidhu MD University of Louisville Gastroenterology, Hepatology and Nutrition June 21, 2012 OVERVIEW Definition Susceptibility The Changing Clinical Presentation Medical
More informationShould you be Gluten Free? Gluten Sensitivity: Today s Most Under Recognized Medical Condition. Disclosures. Gluten Confusion 2/10/2014
Disclosures Gluten Sensitivity: Today s Most Under Recognized Medical Condition Author: South Beach Diet Gluten Solution Arthur Agatston Should you be Gluten Free? Gluten Confusion What is gluten? What
More informationActivation of Innate and not Adaptive Immune system in Gluten Sensitivity
Activation of Innate and not Adaptive Immune system in Gluten Sensitivity Update: Differential mucosal IL-17 expression in gluten sensitivity and the autoimmune enteropathy celiac disease A. Sapone, L.
More informationCeliac Disease: You ve Come A Long Way Baby!
Celiac Disease: You ve Come A Long Way Baby! Celiac Disease (CD): How You ve Changed Increasing numbers of people have celiac disease Changing ways in which celiac disease presents A better understanding
More informationImmune mediated enteropathies. Aurora Tatu Bern 26/07/2017
Immune mediated enteropathies Aurora Tatu Bern 26/07/2017 Definition/classification Systemic disease, mediated by antibodies, caracterised by histological changes of the small bowel Coeliac and noncoeliac
More informationCeliac Disease and Non Celiac Gluten Sensitivity. John R Cangemi, MD Mayo Clinic Florida
Celiac Disease and Non Celiac Gluten Sensitivity John R Cangemi, MD Mayo Clinic Florida DISCLOSURE Commercial Interest None Off Label Usage None Learning Objectives Review the clinical presentation of
More informationCeliac Disease. Educational Gaps. Objectives. Tracy R. Ediger, MD, PhD,* Ivor D. Hill, MB, CHB, MD
Celiac Disease Tracy R. Ediger, MD, PhD,* Ivor D. Hill, MB, CHB, MD *Department of Clinical Pediatrics, The Ohio State University College of Medicine, and Department of Gastroenterology, Hepatology, and
More informationGliadin antibody detection in gluten
The Ulster Medical Journal, Volume 55, No. 2, pp. 160-164, October 1986. Gliadin antibody detection in gluten enteropathy R G P Watson, S A McMillan, Clare Dolan, Cliona O'Farrelly, R J G Cuthbert, Margaret
More informationCeliac Disease: The Future. Alessio Fasano, M.D. Mucosal Biology Research Center University of Maryland School of Medicine
Celiac Disease: The Future Alessio Fasano, M.D. Mucosal Biology Research Center University of Maryland School of Medicine Normal small bowel Celiac disease Gluten Gluten-free diet Treatment Only treatment
More informationScreening for Celiac Disease: A Systematic Review for the U.S. Preventive Services Task Force
Evidence Synthesis Number 144 Screening for Celiac Disease: A Systematic Review for the U.S. Preventive Services Task Force Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health
More informationCeliac Disease The Great Masquerader Anca M. Safta MD
Celiac Disease The Great Masquerader Anca M. Safta MD Disclosures Dr. Anca Safta - none Angie Almond, M.Ed., RD, LDN invited attendee of The Gluten Free Summit sponsored by General Mills Wake Forest Baptist
More informationUtility in Clinical Practice of Immunoglobulin A Anti-Tissue Transglutaminase Antibody for the Diagnosis of Celiac Disease
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2006;4:726 730 Utility in Clinical Practice of Immunoglobulin A Anti-Tissue Transglutaminase Antibody for the Diagnosis of Celiac Disease JULIAN A. ABRAMS,* PARDEEP
More informationCeliac disease (CD) is a gluten-sensitive enteropathy with. Comparative Usefulness of Deamidated Gliadin Antibodies in the Diagnosis of Celiac Disease
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2008;6:426 432 Comparative Usefulness of Deamidated Gliadin Antibodies in the Diagnosis of Celiac Disease SHADI RASHTAK,* MICHAEL W. ETTORE, HENRY A. HOMBURGER,
More informationCeliac Disease: A Holistic Review
Celiac Disease: A Holistic Review Ryan Seals B.S. (Bachelor of Science) Celiac disease is a condition characterized by an abnormality of the small intestine caused by the consumption of gluten in the diet.
More information4/6/18. A clinical and practical presentation of Celiac Disease. Objectives. History of Celiac disease. Lacey Yzeik, MS, RDN, LDN Clinical Dietitian
A clinical and practical presentation of Celiac Disease Lacey Yzeik, MS, RDN, LDN Clinical Dietitian Objectives Define Celiac disease and the modern clinical practices (Type, pathophysiology, symptoms,
More informationCeliac Disease. Etiology. Food Intolerance:Celiac Disease and Gluten Sensitivity-A Guide for Healthy Lifestyles
Food Intolerance:Celiac Disease and Gluten Sensitivity-A Guide for Healthy Lifestyles Ellen Karlin 2017 Celiac Disease World s most common genetic food disorder Rising prevalence - over past 5 decades,
More informationCeliac Disease Myths. Objectives. We Now Know. Classical Celiac Disease. A Clinical Update in Celiac Disease
4:15 5:00pm Presenter Disclosure Information A Clinical Update in Celiac Disease SPEAKER Benjamin Lebwohl, MD, MS The following relationships exist related to this presentation: Benjamin Lebwohl, MD, MS
More informationARTICLE. Emerging New Clinical Patterns in the Presentation of Celiac Disease
ARTICLE Emerging New Clinical Patterns in the Presentation of Celiac Disease Grzegorz Telega, MD; Tess Rivera Bennet, MD; Steven Werlin, MD Objective: To evaluate changes in the clinical presentation of
More informationCurrent Management of Celiac Disease and Identifying an Appropriate Patient Population(s) for Pharmacologic Therapies in Adult Patients
Current Management of Celiac Disease and Identifying an Appropriate Patient Population(s) for Pharmacologic Therapies in Adult Patients Joe Murray The Mayo Clinic 1 DISCLOSURES Relevant Financial Relationship(s)
More informationInternational Journal of Health Sciences and Research ISSN:
International Journal of Health Sciences and Research www.ijhsr.org ISSN: 2249-9571 Original Research Article Role of Blood TTG and Small Intestine Biopsy in Diagnosis of Celiac Disease Anil Batta Professor,
More informationWhat is celiac disease?
What is celiac disease? Celiac disease is a digestive disease that damages the small intestine and interferes with absorption of nutrients from food. People who have celiac disease cannot tolerate gluten,
More informationCeliac disease Crohn s disease Ulcerative colitis Pseudomembranous colitis
2017 / 2018 2nd semester/3rd practice Celiac disease Crohn s disease Ulcerative colitis Pseudomembranous colitis Semmelweis University 2nd Department of Pathology CELIAC DISEASE = Gluten-sensitive enteropathy
More informationImuPro shows you the way to the right food for you. And your path for better health.
Your personal ImuPro Screen + documents Sample ID: 33333 Dear, With this letter, you will receive the ImuPro result for your personal IgG food allergy test. This laboratory report contains your results
More informationCoeliac disease catering gluten-free
Coeliac disease catering gluten-free About Coeliac UK National Charity for people with coeliac disease and dermatitis herpetiformis Founded in 1968 and is the largest coeliac charity in the world Mission:
More informationGluten sensitivity in Multiple Sclerosis Experimental myth or clinical truth?
Gluten sensitivity in Multiple Sclerosis Experimental myth or clinical truth? Annals of the New York Academy of Sciences, Vol 1173, Issue 1, page 44, Issue published online 3 Sep 2009. Dana Ben-Ami Shor,
More informationPOLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY
Original Issue Date (Created): August 9, 2002 Most Recent Review Date (Revised): March 25, 2014 Effective Date: June 1, 2014 POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT
More informationCeliac Disease For Dummies By Sheila Crowe, Ian Blumer READ ONLINE
Celiac Disease For Dummies By Sheila Crowe, Ian Blumer READ ONLINE Celiac disease definition, a hereditary digestive disorder involving intolerance to gluten, usually occurring in young children, characterized
More informationSunderland Guidance on Prescribing Gluten Free Products
Sunderland Guidance on Prescribing Gluten Free Products Gluten free products have ACBS (Advisory Committee on Borderline Substances) approval on the basis that they may be regarded as drugs for the management
More informationGUIDANCE ON THE DIAGNOSIS AND MANAGEMENT OF LACTOSE INTOLERANCE
GUIDANCE ON THE DIAGNOSIS AND MANAGEMENT OF LACTOSE INTOLERANCE These are the lactose intolerance guidelines and it is recommended that they are used in conjunction with the Cow s Milk Allergy guidance.
More information2013 NASPGHAN FOUNDATION
2 Alessio Fasano, MD Visiting Professor of Pediatrics Harvard Medical School Chief of Pediatric Gastroenterology and Nutrition MassGeneral Hospital for Children Director, Center for Celiac Research Director,
More informationPediatric Food Allergies: Physician and Parent. Robert Anderson MD Rachel Anderson Syracuse, NY March 3, 2018
Pediatric Food Allergies: Physician and Parent Robert Anderson MD Rachel Anderson Syracuse, NY March 3, 2018 Learning Objectives Identify risk factors for food allergies Identify clinical manifestations
More information5/27/2014 WEBINAR. Suggested CDR Learning Codes: 3000, 5000, 5110, 5220; Level 2
WEBINAR Alessio Fasano, MD Visiting Professor of Pediatrics Harvard Medical School Chief of Pediatric Gastroenterology and Nutrition MassGeneral Hospital for Children Director, Center for Celiac Research
More informationFood Intolerance & Expertise SARAH KEOGH CONSULTANT DIETITIAN EATWELL FOOD & NUTRITION
Food Intolerance & Expertise SARAH KEOGH CONSULTANT DIETITIAN EATWELL FOOD & NUTRITION Food Intolerance & Expertise What is food intolerance? Common food intolerances Why are consumers claiming more food
More informationCeliac Disease: The Quintessential Autoimmune Disease Ivor D. Hill, MB, ChB, MD.
Celiac Disease: The Quintessential Autoimmune Disease Ivor D. Hill, MB, ChB, MD..... Celiac Disease Autoimmune Diseases What are they? How do you get them? Why does it matter? Celiac Disease Autoimmune
More informationGuideline for the Prescribing of Gluten Free Products (NUT5)
Guideline for the Prescribing of Gluten Free Products (NUT5) Author Medicines Optimisation Team, Sunderland CCG Approved by Sunderland Medicines Optimisation and Guideline Group Current Version 2 Published
More informationLarazotide Acetate. Alessio Fasano, M.D. Mucosal Biology Research Center and Center for Celiac Research University of Maryland School of Medicine
Larazotide Acetate Alessio Fasano, M.D. Mucosal Biology Research Center and Center for Celiac Research University of Maryland School of Medicine Alternative/Integrative Approaches To The Gluten Free Diet
More informationWhat is celiac disease? How common is celiac disease? Who gets celiac disease?
FAQ General What is celiac disease? How common is celiac disease? Who gets celiac disease? What are the symptoms of celiac disease? When does celiac disease usually develop? What is the difference between
More information